Audit of carbapenem prescriptions comparing 2 assessment periods.

作者: A. Lefébure , E. Papy , C. Rioux , S. Diamantis , L. Armand-Lefèvre

DOI: 10.1016/J.MEDMAL.2015.04.008

关键词: CarbapenemMedical prescriptionAntibiotic useContext (language use)Significant differencePsychological interventionIntensive care medicineEpidemiologyAuditMedicine

摘要: Abstract Objective The emergence of extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae has resulted in the increase carbapenem prescriptions. objective our study was to determine appropriateness prescriptions from initiation reassessment treatment, between 2009 and 2011. Patients method A questionnaire drafted by infectious diseases specialists (IDS) microbiologists used collect clinical microbiological data concerning An IDS then compared results assess prescription compliance with hospital's local recommendations. Results Seventy-one were included 32 treatment had been most frequently probabilistic treat nosocomial infections. revealed that number multidrug-resistant (MDR) infections increased 2011, especially involving ESBL-producing . At reassessment, 15 (21%) 12 (38%) appropriate continued. Overall, when comparing 2 periods, complied guidelines without any statistically significant difference (68% 75% 2011). Conclusion Our showed MDR due ; this consistent epidemiological data. We also proved compliant mobile interventions medical surgical departments helped reach rate compliance. Carbapenem stewardship may be promoted even a difficult context, for duration or at reassessment.

参考文章(12)
P. Lesprit, A. de Pontfarcy, M. Esposito-Farese, H. Ferrand, J.L. Mainardi, M. Lafaurie, P. Parize, C. Rioux, F. Tubach, J.C. Lucet, Postprescription review improves in-hospital antibiotic use: a multicenter randomized controlled trial. Clinical Microbiology and Infection. ,vol. 21, pp. 180- ,(2015) , 10.1016/J.CMI.2014.08.015
P.M. Hawkey, Prevalence and clonality of extended-spectrum β-lactamases in Asia Clinical Microbiology and Infection. ,vol. 14, pp. 159- 165 ,(2008) , 10.1111/J.1469-0691.2007.01855.X
T. Delory, A. Pontfarcy, A. Emirian, F. About, B. Berdougo, C. Brun-Buisson, P. Lesprit, Impact of a program combining pre-authorization requirement and post-prescription review of carbapenems: an interrupted time-series analysis European Journal of Clinical Microbiology & Infectious Diseases. ,vol. 32, pp. 1599- 1604 ,(2013) , 10.1007/S10096-013-1918-5
P. Nordmann, A. Carrer, Les carbapénèmases des entérobactéries Archives de Pédiatrie. ,vol. 17, pp. S154- S162 ,(2010) , 10.1016/S0929-693X(10)70918-0
M.V. Villegas, J.N. Kattan, M.G. Quinteros, J.M. Casellas, Prevalence of extended-spectrum β-lactamases in South America Clinical Microbiology and Infection. ,vol. 14, pp. 154- 158 ,(2008) , 10.1111/J.1469-0691.2007.01869.X
P. M. Hawkey, A. M. Jones, The changing epidemiology of resistance. Journal of Antimicrobial Chemotherapy. ,vol. 64, ,(2009) , 10.1093/JAC/DKP256
David L. Paterson, Robert A. Bonomo, Extended-spectrum beta-lactamases: a clinical update. Clinical Microbiology Reviews. ,vol. 18, pp. 657- 686 ,(2005) , 10.1128/CMR.18.4.657-686.2005
K. Z. Vardakas, G. S. Tansarli, P. I. Rafailidis, M. E. Falagas, Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis Journal of Antimicrobial Chemotherapy. ,vol. 67, pp. 2793- 2803 ,(2012) , 10.1093/JAC/DKS301